Lee D D, Grossman E, Chong A S
Section of Transplantation, Department of Surgery, The University of Chicago, IL 60637, USA.
Horm Metab Res. 2008 Feb;40(2):147-54. doi: 10.1055/s-2008-1042430.
Type 1 diabetes mellitus (T1DM) is a disease that results from the selective autoimmune destruction of insulin-producing beta-cells. This disease process lends itself to cellular therapy because of the single cell nature of insulin production. Murine models have provided opportunities for the study of cellular therapies for the treatment of diabetes, including the investigation of islet transplantation, and also the possibility of stem cell therapies and islet regeneration. Studies in islet transplantation have included both allo- and xeno-transplantation and have allowed for the study of new approaches for the reversal of autoimmunity and achieving immune tolerance. Stem cells from hematopoietic sources such as bone marrow and fetal cord blood, as well as from the pancreas, intestine, liver, and spleen promise either new sources of islets or may function as stimulators of islet regeneration. This review will summarize the various cellular interventions investigated as potential treatments of T1DM.
1型糖尿病（T1DM）是一种由于胰岛素生成β细胞被选择性自身免疫破坏而导致的疾病。由于胰岛素产生的单细胞性质，这种疾病过程适合进行细胞治疗。小鼠模型为糖尿病细胞治疗的研究提供了机会，包括胰岛移植的研究，以及干细胞治疗和胰岛再生的可能性。胰岛移植的研究包括同种异体移植和异种移植，并为研究自身免疫逆转和实现免疫耐受的新方法提供了可能。来自骨髓和胎儿脐带血等造血来源以及胰腺、肠道、肝脏和脾脏的干细胞有望成为新的胰岛来源，或可能起到胰岛再生刺激剂的作用。本综述将总结作为T1DM潜在治疗方法而研究的各种细胞干预措施。
